Loading organizations...
§ Private Profile · Barcelona, Spain
Intergovernmental organization resolving international disputes through mediation, focusing on interstate, investment, and commercial conflicts.
IOMED is the world's first intergovernmental organization dedicated to resolving international disputes through mediation, including interstate, investment, and commercial conflicts, based in Wan Chai, Hong Kong Special Administrative Region, China. The organization promotes peaceful dispute settlement, primarily serving developing countries, with its convention signed by 33 countries and ratified by 8 by October 2025. Its first Governing Council, comprising 8 contracting states, commenced operations following the central office inauguration. Key founding members include China, Indonesia, Pakistan, Laos, and Serbia, with leadership featuring Secretary-General Teresa Cheng SC and Governing Council Chair HUA Chunying. The concept was announced in October 2022, and the convention was signed on May 30, 2025, entering into force on August 29, 2025. The firm focuses on international dispute mediation for governments and international organizations, primarily serving developing countries in Asia, Africa, Latin America, and Europe, many linked to China's Belt and Road Initiative.
IOMED has raised $27.8M across 5 funding rounds.
IOMED has raised $27.8M in total across 5 funding rounds.
IOMED has raised $27.8M in total across 5 funding rounds.
IOMED's investors include Alexandre Perrin, Philips Ventures, XTX Ventures, Adara Ventures, EASO Ventures, Fondo Bolsa Social, red.es, Redseed, Ada Ventures, Human Augmentation Syndicate, Scalebridge Capital, Alan MacIntosh.
IOMED is a Barcelona-based health tech company founded in 2016 that builds an AI-powered Data Space Platform to activate and standardize healthcare data from structured and unstructured sources, including electronic health records (EHR) and human-written notes.[1][2][3][5] It serves healthcare organizations (data holders like hospitals), research organizations, and contract research organizations (data users) by solving the problem of unlocking raw, siloed clinical data for secondary use—such as research, clinical trials, and data-driven decision-making—while ensuring compliance, data privacy via federated models (data never leaves hospital systems), and standardization to the OMOP Common Data Model.[1][3][4] With $6 million in 2025 revenue, 41-57 employees, over 21 million patients' data activated, 50+ strategic partners, 13+ active hospitals, and 40+ research projects, IOMED demonstrates strong growth momentum, including international expansion and certifications like ISO 27001, EHDEN, and OHDSI partnership.[1][3]
IOMED's idea emerged in 2015 when co-founder Gabriel Maeztu, during his research, identified inefficiencies in data collection and patient recruitment from unstructured healthcare records.[5] In 2016, Maeztu, along with co-founders Álvaro Abella and Javier de Oca, launched the company in Castelldefels, Catalonia (near Barcelona), developing AI and Natural Language Processing (NLP) technology to bridge this gap.[1][5][6] Early deployment in Barcelona hospitals led to nationwide expansion in Spain by 2020, marked by a €2 million funding round led by Adara Ventures (with EASO Ventures and Speedinvest) to grow into Germany and the UK; pivotal moments include exponential traction, peer-reviewed publications, and evolution into a global Data Space Mediator.[5][6] Today, Gabriel Maeztu serves as Co-Founder, President, and CTO.[1]
IOMED rides the wave of the European Health Data Space (EHDS) and global push for real-world evidence (RWE) in healthcare, where fragmented, unstructured data (90% of records) hinders AI-driven research, personalized medicine, and clinical trials.[3][4][5] Timing is ideal amid EU regulations mandating data interoperability (e.g., OMOP/OHDSI standards) and post-pandemic demand for federated learning to balance privacy with collaboration, positioning IOMED as a key mediator in a market projected to grow with health data spaces.[3][4] Favorable forces include rising RWD needs for drug development, hospital digitalization, and AI adoption; IOMED influences the ecosystem by powering 450K+ impacted patients, 45+ research projects, and cross-border networks, fostering a data-driven healthcare shift while upholding ethical standards.[3]
IOMED is poised for accelerated European and global scaling as EHDS rolls out, leveraging its federated network and AI edge to capture demand from pharma, CROs, and hospitals seeking compliant RWE.[3][5] Trends like multimodal AI, predictive analytics, and multinational data commons will amplify its role, potentially driving revenue beyond $6M through new partnerships and U.S./Asia entry. Its influence may evolve from enabler to standard-setter in health data spaces, transforming siloed records into evidence-based care—IOMED isn't just activating data; it's powering the future of precision healthcare.[1][3][5]
IOMED has raised $27.8M across 5 funding rounds. Most recently, it raised $11.8M Grant / Series A in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 13, 2023 | $11.8M Grant | Alexandre Perrin, Philips Ventures, XTX Ventures | Adara Ventures, Easo Ventures, Fondo Bolsa Social, Red.es, Redseed | Announced |
| Sep 1, 2023 | $11M Series A | — | Adara Ventures, ADA Ventures, Human Augmentation Syndicate, Scalebridge Capital, Alan Macintosh, Charlie Songhurst, Evan Cheng | Announced |
| Sep 3, 2020 | $2.4M Venture Round | Rocio Pillado | Easo Ventures, Speedinvest | Announced |
| Sep 1, 2020 | $2M Seed | — | Adara Ventures | Announced |
| Jul 18, 2018 | $580K Venture Round | Easo Ventures | Pioneers Ventures | Announced |